Take This Into Account Before Investing in PSTX

Small-cap Healthcare company Poseida Therapeutics has moved 15.5% so far today on a volume of 731,504, compared to its average of 452,737. In contrast, the S&P 500 index moved 0.8%.

Poseida Therapeutics trades -54.68% away from its average analyst target price of $14.75 per share. The 4 analysts following the stock have set target prices ranging from $10 to $24, and on average have given Poseida Therapeutics a rating of strong buy.

Anyone interested in buying PSTX should be aware of the facts below:

  • Poseida Therapeutics has moved -11.2% over the last year, and the S&P 500 logged a change of -18.6%

  • Based on its trailing earning per share of -2.32, Poseida Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of -2.9 while the S&P 500 average is 15.97

  • PSTX has a forward P/E ratio of -2.8 based on its forward 12 month price to earnings (Eps) of $-2.43 per share

  • The company has a price to earnings growth (PEG) ratio of -4.4 — a number near or below 1 signifying that Poseida Therapeutics is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 2.7 compared to its sector average of 4.07

  • Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs.

  • Based in San Diego, the company has 304 full time employees and a market cap of $574,571,712.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.